Edgar Snyder & Associates®
A Law Firm Representing Injured People
1-866-943-3427
Call Us Toll Free 24/7
Published on Jan 02, 2007 by Edgar Snyder

Serious Side Effect Associated with Rituxan

Rituxan

The Food and Drug Administration (FDA) warns of a serious risk associated the drug Rituxan. Two patients that were treated with the drug for systemic lupus erythematosus (SLE) contracted progressive multifocal leukoencephalopathy (PML), a fatal viral infection that attacks the central nervous system.

Rituxan is approved to treat patients with non-Hodgkin’s lymphoma and those with rheumatoid arthritis. Rituxan is not an approved for treatment of SLE, and symptoms of PML appeared up to months after a final dose of Rituxan. The drug’s label was updated in February 2006 to include a risk of serious viral infections, including PML, in patients with lymphoma.

Patients who have been treated with Rituxan and experience changes in their vision, balance, or coordination, or who are confused should contact their doctors immediately.

Free Case Review
First Name
Last Name
ZIP
Phone
Email
Briefly describe your injuries
Please note: All of our lawyers are licensed to practice in the state of Pennsylvania. We also have lawyers licensed to practice in Ohio, and West Virginia and we associate with experienced attorneys in other states. In addition, all drug-related litigation involves co-counsel.

Source: “FDA Warns of Safety Concern Regarding Rituxan in New Patient Population.” FDA News. December 18, 2006.
Think you have a case?
Think you have a case?
Free Case Review
First Name
Last Name
ZIP
Phone
Email
Briefly describe your injuries

Recent News

Sep 28, 2016
Pittsburgh Police Beefing Up DUI Patrols in 2017
Sep 26, 2016
Gear Up, Cool Down, and Stay Safe While Riding This Fall
Sep 16, 2016
Fall and Winter Car Kit
Sep 16, 2016
A New Law May Be Coming for Drivers
Sep 16, 2016
Smartphone Apps for Drivers
Tweet